Literature DB >> 14722201

Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha.

J van der Heijden1, M C de Jong, B A C Dijkmans, W F Lems, R Oerlemans, I Kathmann, C G Schalkwijk, G L Scheffer, R J Scheper, G Jansen.   

Abstract

OBJECTIVE: To determine whether overexpression of cell membrane associated drug efflux pumps belonging to the family of ATP binding cassette (ABC) proteins contributes to a diminished efficacy of sulfasalazine (SSZ) after prolonged cellular exposure to this disease modifying antirheumatic drug (DMARD).
METHODS: A model system of human T cells (CEM) was used to expose cells in vitro to increasing concentrations of SSZ for a period of six months. Cells were then characterised for the expression of drug efflux pumps: P-glycoprotein (Pgp, ABCB1), multidrug resistance protein 1 (MRP1, ABCC1), and breast cancer resistance protein (BCRP, ABCG2).
RESULTS: Prolonged exposure of CEM cells to SSZ provoked resistance to SSZ as manifested by a 6.4-fold diminished antiproliferative effect of SSZ compared with parental CEM cells. CEM cells resistant to SSZ (CEM/SSZ) showed a marked induction of ABCG2/BCRP, Pgp expression was not detectable, while MRP1 expression was even down regulated. A functional role of ABCG2 in SSZ resistance was demonstrated by 60% reversal of SSZ resistance by the ABCG2 blocker Ko143. Release of the proinflammatory cytokine tumour necrosis factor alpha (TNFalpha) was threefold higher in CEM/SSZ cells than in CEM cells. Moreover, twofold higher concentrations of SSZ were required to inhibit TNFalpha release from CEM/SSZ cells compared with CEM cells.
CONCLUSION: Collectively, ABCG2 induction, augmented TNFalpha release, and less efficient inhibition of TNFalpha production by SSZ may contribute to diminished efficacy after prolonged exposure to SSZ. These results warrant further clinical studies to verify whether drug efflux pumps, originally identified for their roles in cytostatic drug resistance, can also be induced by SSZ or other DMARDs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722201      PMCID: PMC1754889          DOI: 10.1136/ard.2002.005249

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  65 in total

Review 1.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter.

Authors:  S V Ambudkar; S Dey; C A Hrycyna; M Ramachandra; I Pastan; M M Gottesman
Journal:  Annu Rev Pharmacol Toxicol       Date:  1999       Impact factor: 13.820

2.  Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR.

Authors:  M de Bruin; K Miyake; T Litman; R Robey; S E Bates
Journal:  Cancer Lett       Date:  1999-11-15       Impact factor: 8.679

3.  CONTINUOUS CULTURE OF HUMAN LYMPHOBLASTS FROM PERIPHERAL BLOOD OF A CHILD WITH ACUTE LEUKEMIA.

Authors:  G E FOLEY; H LAZARUS; S FARBER; B G UZMAN; B A BOONE; R E MCCARTHY
Journal:  Cancer       Date:  1965-04       Impact factor: 6.860

Review 4.  Complete characterization of the human ABC gene family.

Authors:  M Dean; R Allikmets
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

5.  COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention.

Authors:  Robert B M Landewé; Maarten Boers; Arco C Verhoeven; Rene Westhovens; Mart A F J van de Laar; Harry M Markusse; J Christiaan van Denderen; Marie Louise Westedt; Andre J Peeters; Ben A C Dijkmans; Piet Jacobs; Annelies Boonen; Désirée M F M van der Heijde; Sjef van der Linden
Journal:  Arthritis Rheum       Date:  2002-02

Review 6.  An inventory of the human ABC proteins.

Authors:  I Klein; B Sarkadi; A Váradi
Journal:  Biochim Biophys Acta       Date:  1999-12-06

7.  Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2.

Authors:  J H Hooijberg; H J Broxterman; M Kool; Y G Assaraf; G J Peters; P Noordhuis; R J Scheper; P Borst; H M Pinedo; G Jansen
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

8.  Suppression of TNFalpha-mediated NFkappaB activity by myricetin and other flavonoids through downregulating the activity of IKK in ECV304 cells.

Authors:  S H Tsai; Y C Liang; S Y Lin-Shiau; J K Lin
Journal:  J Cell Biochem       Date:  1999-09-15       Impact factor: 4.429

9.  Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.

Authors:  D D Ross; W Yang; L V Abruzzo; W S Dalton; E Schneider; H Lage; M Dietel; L Greenberger; S P Cole; L A Doyle
Journal:  J Natl Cancer Inst       Date:  1999-03-03       Impact factor: 13.506

10.  Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine.

Authors:  S Liptay; M Bachem; G Häcker; G Adler; K M Debatin; R M Schmid
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

View more
  20 in total

1.  Acquired resistance of human T cells to sulfasalazine.

Authors:  D E Furst
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

2.  Inhibition of human MDR1 and BCRP transporter ATPase activity by organochlorine and pyrethroid insecticides.

Authors:  Kristin M Bircsak; Jason R Richardson; Lauren M Aleksunes
Journal:  J Biochem Mol Toxicol       Date:  2012-11-20       Impact factor: 3.642

3.  Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

Authors:  A Finckh; J F Simard; C Gabay; P-A Guerne
Journal:  Ann Rheum Dis       Date:  2005-12-08       Impact factor: 19.103

Review 4.  Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.

Authors:  Qingcheng Mao; Jashvant D Unadkat
Journal:  AAPS J       Date:  2014-09-19       Impact factor: 4.009

Review 5.  The challenge of exploiting ABCG2 in the clinic.

Authors:  Robert W Robey; Caterina Ierano; Zhirong Zhan; Susan E Bates
Journal:  Curr Pharm Biotechnol       Date:  2011-04       Impact factor: 2.837

6.  Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor alpha and glucocorticoid induced apoptosis.

Authors:  Ruud Oerlemans; Josefien Vink; Ben A C Dijkmans; Yehuda G Assaraf; Marjolein van Miltenburg; Joost van der Heijden; Ilan Ifergan; Willem F Lems; Rik J Scheper; Gertjan J L Kaspers; Jacqueline Cloos; Gerrit Jansen
Journal:  Ann Rheum Dis       Date:  2007-01-31       Impact factor: 19.103

7.  Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance.

Authors:  Eran E Bram; Michal Stark; Shachar Raz; Yehuda G Assaraf
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

8.  Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs.

Authors:  J van der Heijden; M C de Jong; B A C Dijkmans; W F Lems; R Oerlemans; I Kathmann; G L Scheffer; R J Scheper; Y G Assaraf; G Jansen
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

9.  Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.

Authors:  Bradley L Urquhart; Joseph A Ware; Rommel G Tirona; Richard H Ho; Brenda F Leake; Ute I Schwarz; Hani Zaher; Joe Palandra; Jamie C Gregor; George K Dresser; Richard B Kim
Journal:  Pharmacogenet Genomics       Date:  2008-05       Impact factor: 2.089

10.  Expression of multidrug resistance-1 protein correlates with disease activity rather than the refractoriness to methotrexate therapy in rheumatoid arthritis.

Authors:  V Agarwal; S K Mittal; R Misra
Journal:  Clin Rheumatol       Date:  2009-01-10       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.